[go: up one dir, main page]

IL229260A0 - Compositions,methods & systems for respiratory delivery of two or more active agents - Google Patents

Compositions,methods & systems for respiratory delivery of two or more active agents

Info

Publication number
IL229260A0
IL229260A0 IL229260A IL22926013A IL229260A0 IL 229260 A0 IL229260 A0 IL 229260A0 IL 229260 A IL229260 A IL 229260A IL 22926013 A IL22926013 A IL 22926013A IL 229260 A0 IL229260 A0 IL 229260A0
Authority
IL
Israel
Prior art keywords
compositions
systems
methods
active agents
respiratory delivery
Prior art date
Application number
IL229260A
Other languages
Hebrew (he)
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of IL229260A0 publication Critical patent/IL229260A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00Disinfection, sterilisation or deodorisation of air
    • A61L9/015Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/02Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL229260A 2011-05-17 2013-11-05 Compositions,methods & systems for respiratory delivery of two or more active agents IL229260A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/036868 WO2012158166A1 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (1)

Publication Number Publication Date
IL229260A0 true IL229260A0 (en) 2014-01-30

Family

ID=47177229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229260A IL229260A0 (en) 2011-05-17 2013-11-05 Compositions,methods & systems for respiratory delivery of two or more active agents

Country Status (14)

Country Link
EP (1) EP2709447A4 (en)
JP (1) JP2014518871A (en)
KR (1) KR20140032404A (en)
CN (1) CN103687483A (en)
AU (1) AU2011368334A1 (en)
BR (1) BR112013029507A2 (en)
CA (1) CA2835927A1 (en)
EA (1) EA201490991A1 (en)
IL (1) IL229260A0 (en)
MX (1) MX2013013440A (en)
PH (1) PH12013502270A1 (en)
RU (1) RU2013155903A (en)
SG (1) SG194896A1 (en)
WO (1) WO2012158166A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5873013B2 (en) 2009-05-29 2016-03-01 パール セラピューティクス,インコーポレイテッド Compositions, methods and systems for respiratory delivery of two or more active agents
JP2016506947A (en) 2013-01-31 2016-03-07 プロソニックス リミテッド Pharmaceutical composition comprising multicomponent crystal particles suitable for use in inhalation therapy
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
SG11201509543YA (en) * 2013-05-22 2015-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of three or more active agents
ES2666905T4 (en) * 2013-12-30 2018-06-07 Chiesi Farmaceutici S.P.A. Composition in solution for pressurized stable aerosol of a combination of glycopyrronium bromide and formoterol
CN105848641B (en) 2013-12-30 2021-07-09 奇斯药制品公司 Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
MY181647A (en) 2014-09-09 2020-12-30 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
BR112017023351B1 (en) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION
CN105125542A (en) * 2015-08-23 2015-12-09 杭州紫金医药科技有限公司 Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation
CN106880637B (en) * 2015-12-15 2021-01-29 天津金耀集团有限公司 Ciclesonide formoterol and tiotropium bromide compound dry powder inhalant composition
CN106880636A (en) * 2015-12-15 2017-06-23 天津金耀集团有限公司 A kind of ciclesonide folk prescription and compound dry powder inhalation composition
CN106943350A (en) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 Aerosol and preparation method containing muscarinic receptor antagonist and β 2 receptor agonist
WO2020100040A1 (en) * 2018-11-12 2020-05-22 3M Innovative Properties Company Umeclidinium and vilanterol formulation and inhaler
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN111467498A (en) * 2020-05-14 2020-07-31 王兆霖 Pharmaceutical composition preparation
TW202241410A (en) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutical composition delivered by metered dose inhaler
SMT202400370T1 (en) * 2021-07-09 2024-11-15 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999016422A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
PL1718336T3 (en) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5873013B2 (en) * 2009-05-29 2016-03-01 パール セラピューティクス,インコーポレイテッド Compositions, methods and systems for respiratory delivery of two or more active agents

Also Published As

Publication number Publication date
MX2013013440A (en) 2014-06-05
PH12013502270A1 (en) 2014-01-27
KR20140032404A (en) 2014-03-14
CA2835927A1 (en) 2012-11-22
CN103687483A (en) 2014-03-26
AU2011368334A1 (en) 2013-11-21
EP2709447A4 (en) 2014-10-22
SG194896A1 (en) 2013-12-30
RU2013155903A (en) 2015-06-27
JP2014518871A (en) 2014-08-07
BR112013029507A2 (en) 2019-09-24
WO2012158166A1 (en) 2012-11-22
EP2709447A1 (en) 2014-03-26
EA201490991A1 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
IL229260A0 (en) Compositions,methods & systems for respiratory delivery of two or more active agents
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
ZA201903184B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1221653A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
EP2841138A4 (en) Aerosol delivery systems, compositions and methods
HK1232073A1 (en) Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
MY168300A (en) Pharmaceutical Composition for Inhalation
PL2841549T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
PL2841548T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
HK1208188A1 (en) Formulations for the delivery of active ingredients
HK1179534A1 (en) Coated preparation containing azosemide as active ingredient
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
HUE047420T2 (en) Dosage form for the controlled release of active ingredients
IL232944A0 (en) Nasal formulation
HK1203068A1 (en) Systems and methods for generating germicidal compositions